Faeth Therapeutics, Inc.
NASDAQ:FTHBiotechnology
+$1.43 today
- Market cap
- $224.79M
- Beta
- -0.31
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$34.65
Volume 0.33M
Average 0.12M
FTH Account Payables
Amounts the company owes suppliers for goods and services received.
Faeth Therapeutics, Inc.NASDAQ: FTH
Account Payables · Q2 FY2026 · quarter ended Jun 2026
Account payables rises 511.7% from a year ago
Account payables stood at $2.15M at the end of Q2 FY2026, up 511.7% from a year earlier and down 37.2% from the prior quarter. Over 3 fiscal years it compounded at -46.4% a year.
Context
- Account payables amounted to 1.1% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +511.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 689K USD
- Year-over-year change
- +182.4%
- 4-year CAGR
- -27.2%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 689K | +182.4% |
| FY2024 | 2024-12-31 | 244K | -85.6% |
| FY2023 | 2023-12-31 | 1.69M | -62.1% |
| FY2022 | 2022-12-31 | 4.47M | +82.1% |
| FY2021 | 2021-12-31 | 2.46M | — |
Account Payables vs competitors
How FTH compares with its peers on the latest reported figures
- FTH's Jun 2026 account payables of $2.15M is the 7th highest of the 10 companies compared; the peer median is $7.04M.
- Its year-over-year change of +511.7% is the highest of 10, against a peer median of +35.5%.
- Account payables amounts to 1.1% of total assets for FTH, versus a peer median of 1.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $12.09M | -46.1% | +64.3% | 1.6% | |
| Jun 2026 | $11.46M | +121.4% | -10.0% | 1.2% | |
| Mar 2026 | $9.6M | +33.4% | +36.4% | 4.2% | |
| Mar 2026 | $8.17M | +35.5% | -7.7% | 4.2% | |
| Mar 2026 | $7.04M | +52.8% | +48.5% | 1.1% | |
| Mar 2026 | $3.38M | +43.6% | +32.0% | 0.3% | |
| Jun 2026 | $2.15M | +511.7% | -46.4% | 1.1% | |
| Mar 2026 | $2.07M | -64.5% | -16.2% | 1.7% | |
| Mar 2026 | $2.04M | +49.0% | +2.1% | 1.4% | |
| Sep 2026 | $1.65M | -26.0% | -35.7% | 0.2% | |
| Peer median (excluding FTH) | $7.04M | +35.5% | +2.1% | 1.4% | |
Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7.16M | 17.8M | 13.01M | 9.99M | 8.67M |
| Short-term Investments | 140.46M | 89.32M | 52.75M | 31.34M | 12.52M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 374K | 344K | 325K | 120K | 92K |
| Total Current Assets | 148.54M | 108.59M | 67.25M | 41.93M | 21.51M |
| Property, Plant & Equipment (Net) | 4.64M | 9.72M | 7.04M | 3.38M | 1.38M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 39K | 63K | 86K | 48K | 18K |
| Total Non-current Assets | 4.68M | 9.79M | 7.12M | 3.43M | 1.4M |
| Total Assets | 153.23M | 118.38M | 74.37M | 45.36M | 22.9M |
| Account Payables | 2.46M | 4.47M | 1.69M | 244K | 689K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 2.01M | 1.4M |
| Total Current Liabilities | 4.89M | 9.07M | 5.64M | 5.45M | 4.25M |
| Long-term Debt | 0 | 0 | 0 | 0 | 59K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 149K | 0 | 67K | 0 | 0 |
| Total Non-current Liabilities | 1.82M | 5.9M | 3.84M | 1.53M | 59K |
| Total Liabilities | 6.71M | 14.97M | 9.48M | 6.98M | 4.31M |
| Common Stock | 3K | 3K | 3K | 3K | 0 |
| Retained Earnings | (149.21M) | (197.79M) | (231.9M) | (262.05M) | (283.14M) |
| Accumulated OCI | (333K) | (1M) | (209K) | (13K) | 1K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 146.51M | 103.41M | 64.9M | 38.39M | 18.59M |
| Total Debt | 2.35M | 8.03M | 6.21M | 3.85M | 1.51M |
| Net Debt | (4.81M) | (9.76M) | (6.8M) | (6.15M) | (7.16M) |
Faeth Therapeutics, Inc.
NASDAQ:FTH
Intrinsic Alpha fair value
Locked
Current Price
$8.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.